Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial.

Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N; DIRECT Programme Study Group.

Lancet. 2008 Oct 18;372(9647):1385-93. doi: 10.1016/S0140-6736(08)61411-7. Epub 2008 Sep 25.

2.

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.

Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK; DIRECT Programme Study Group.

Lancet. 2008 Oct 18;372(9647):1394-402. doi: 10.1016/S0140-6736(08)61412-9. Epub 2008 Sep 25.

PMID:
18823656
3.

The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.

Sandset EC, Bath PM, Boysen G, Jatuzis D, Kõrv J, Lüders S, Murray GD, Richter PS, Roine RO, Terént A, Thijs V, Berge E; SCAST Study Group.

Lancet. 2011 Feb 26;377(9767):741-50. doi: 10.1016/S0140-6736(11)60104-9.

PMID:
21316752
4.

Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.

Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Aldington S, Chaturvedi N.

Diabet Med. 2011 Mar;28(3):345-51. doi: 10.1111/j.1464-5491.2010.03210.x.

PMID:
21309844
5.

Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.

Porta M, Hainer JW, Jansson SO, Malm A, Bilous R, Chaturvedi N, Fuller JH, Klein R, Orchard T, Parving HH, Sjølie AK; DIRECT Study Group.

Diabetologia. 2011 Jun;54(6):1298-303. doi: 10.1007/s00125-010-2040-1. Epub 2011 Jan 12.

PMID:
21225239
6.

The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics.

Sjølie AK, Porta M, Parving HH, Bilous R, Klein R; DIRECT Programme Study Group.

J Renin Angiotensin Aldosterone Syst. 2005 Mar;6(1):25-32.

PMID:
16088848
7.

Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.

Bilous R, Chaturvedi N, Sjølie AK, Fuller J, Klein R, Orchard T, Porta M, Parving HH.

Ann Intern Med. 2009 Jul 7;151(1):11-20, W3-4. Epub 2009 May 18.

PMID:
19451554
8.

Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study.

Baguet JP, Asmar R, Valensi P, Nisse-Durgeat S, Mallion JM.

Vasc Health Risk Manag. 2009;5(1):175-83. Epub 2009 Apr 8.

9.

The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design.

Chaturvedi N, Sjoelie AK, Svensson A; DIRECT Programme Study Group.

J Renin Angiotensin Aldosterone Syst. 2002 Dec;3(4):255-61.

PMID:
12584669
10.

A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).

Palma Gámiz JL, Pêgo M, Contreras EM, Anglada MP, Martínez JO, Esquerra EA, Sagastagoitia Gorostiza JD; Iberian Multicenter Imidapril Study on Hypertension.

Clin Ther. 2006 Dec;28(12):2040-51.

PMID:
17296460
11.

The effects of candesartan on diabetes glomerulopathy: a double-blind, placebo-controlled trial.

Perrin NE, Jaremko GA, Berg UB.

Pediatr Nephrol. 2008 Jun;23(6):947-54. doi: 10.1007/s00467-008-0745-x.

PMID:
18270751
12.

Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).

Ogihara T, Ueshima K, Nakao K, Fukiyama K, Oba K, Yasuno S, Fujimoto A, Sato T, Matsuoka H, Saruta T; CASE-J Ex Study Group.

Hypertens Res. 2011 Dec;34(12):1295-301. doi: 10.1038/hr.2011.120. Epub 2011 Aug 11.

PMID:
21833000
13.

Feasibility of treating prehypertension with an angiotensin-receptor blocker.

Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH Jr, Messerli FH, Oparil S, Schork MA; Trial of Preventing Hypertension (TROPHY) Study Investigators.

N Engl J Med. 2006 Apr 20;354(16):1685-97. Epub 2006 Mar 14.

14.

Diabetic retinopathy and blockade of the renin-angiotensin system: new data from the DIRECT study programme.

Wright AD, Dodson PM.

Eye (Lond). 2010 Jan;24(1):1-6. doi: 10.1038/eye.2009.189. Epub 2009 Jul 24. Review.

PMID:
19648902
15.

Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.

Rosei EA, Rizzoni D, Muiesan ML, Sleiman I, Salvetti M, Monteduro C, Porteri E; CENTRO (CandEsartaN on aTherosclerotic Risk factors) study investigators.

J Hypertens. 2005 Feb;23(2):435-44.

PMID:
15662233
16.

Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies.

Wei F, Jia XJ, Yu SQ, Gu Y, Wang L, Guo XM, Wang M, Zhu F, Cheng X, Wei YM, Zhou ZH, Fu M, Liao YH; SOT-AT1 Study Group.

Heart. 2011 Mar;97(6):479-84. doi: 10.1136/hrt.2009.192104. Epub 2011 Feb 4.

PMID:
21296780
17.

A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.

Palma-Gamiz JL, Pêgo M, Marquez E, Pujol M, Olivan J, Alegría E, Sagastagoitia-Gorostiza JD, Gonzalez-Juanatey JR.

Clin Drug Investig. 2007;27(6):407-17.

PMID:
17506591
18.

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen LT, d'Emden MC, Crimet DC, O'Connell RL, Colman PG; FIELD study investigators.

Lancet. 2007 Nov 17;370(9600):1687-97. Epub 2007 Nov 7.

PMID:
17988728
19.

Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.

Knudsen ST, Andersen NH, Poulsen SH, Eiskjaer H, Hansen KW, Helleberg K, Poulsen PL, Mogensen CE.

Am J Hypertens. 2008 Feb;21(2):172-6. doi: 10.1038/ajh.2007.2. Epub 2008 Jan 10.

PMID:
18188164
20.

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.

Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A; SCOPE Study Group.

J Hypertens. 2003 May;21(5):875-86.

PMID:
12714861
Items per page

Supplemental Content

Write to the Help Desk